In addition, administration of PAs in rats with CCl4-induced liver fibrosis resulted in a significant (P < 0.05) improvement in the levels of these biomarkers in serum compared with the CCL4-treated rats. This evidence concerns the gene CCL4 and Hepatic fibrosis.